130 related articles for article (PubMed ID: 27804235)
21. Multisystemic and Multiresistant Langerhans Cell Histiocytosis: A Case Treated With BRAF Inhibitor.
Gandolfi L; Adamo S; Pileri A; Broccoli A; Argnani L; Zinzani PL
J Natl Compr Canc Netw; 2015 Jun; 13(6):715-8. PubMed ID: 26085387
[TBL] [Abstract][Full Text] [Related]
22. New somatic BRAF splicing mutation in Langerhans cell histiocytosis.
Héritier S; Hélias-Rodzewicz Z; Chakraborty R; Sengal AG; Bellanné-Chantelot C; Thomas C; Moreau A; Fraitag S; Allen CE; Donadieu J; Emile JF
Mol Cancer; 2017 Jul; 16(1):115. PubMed ID: 28679432
[TBL] [Abstract][Full Text] [Related]
23. Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.
Schöffski P; Wozniak A; Escudier B; Rutkowski P; Anthoney A; Bauer S; Sufliarsky J; van Herpen C; Lindner LH; Grünwald V; Zakotnik B; Lerut E; Debiec-Rychter M; Marréaud S; Lia M; Raveloarivahy T; Collette S; Albiges L
Eur J Cancer; 2017 Dec; 87():147-163. PubMed ID: 29149761
[TBL] [Abstract][Full Text] [Related]
24. Association between clinicopathologic characteristics and BRAF
Huang H; Lu T; Sun Y; Li S; Li J; Xu K; Feng RE; Xu ZJ
Thorac Cancer; 2019 Oct; 10(10):1984-1992. PubMed ID: 31441596
[TBL] [Abstract][Full Text] [Related]
25. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group.
Minkov M; Grois N; Heitger A; Pötschger U; Westermeier T; Gadner H
Klin Padiatr; 2000; 212(4):139-44. PubMed ID: 10994540
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical and molecular cytogenetic evaluation of potential targets for tyrosine kinase inhibitors in Langerhans cell histiocytosis.
Caponetti GC; Miranda RN; Althof PA; Dobesh RC; Sanger WG; Medeiros LJ; Greiner TC; Weisenburger DD
Hum Pathol; 2012 Dec; 43(12):2223-8. PubMed ID: 22748304
[TBL] [Abstract][Full Text] [Related]
27. Analysis of the BRAFV600E mutation in 19 cases of Langerhans cell histiocytosis in Japan.
Sasaki Y; Guo Y; Arakawa F; Miyoshi H; Yoshida N; Koga Y; Nakashima K; Kurita D; Niino D; Seto M; Ohshima K
Hematol Oncol; 2017 Sep; 35(3):329-334. PubMed ID: 27041734
[TBL] [Abstract][Full Text] [Related]
28. BRAFV600E mutation in cutaneous lesions of patients with adult Langerhans cell histiocytosis.
Varga E; Korom I; Polyánka H; Szabó K; Széll M; Baltás E; Bata-Csörgő Z; Kemény L; Oláh J
J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1205-11. PubMed ID: 25351766
[TBL] [Abstract][Full Text] [Related]
29. Successful treatment with cladribine of Erdheim-Chester disease with orbital and central nervous system involvement developing after treatment of Langerhans cell histiocytosis.
Perić P; Antić B; Knezević-Usaj S; Radić-Tasić O; Radovinović-Tasić S; Vasić-Vilić J; Sekulović L; Tarabar O; Tukić L; Jovandić S; Magić Z
Vojnosanit Pregl; 2016 Jan; 73(1):83-7. PubMed ID: 26964390
[TBL] [Abstract][Full Text] [Related]
30. Clofarabine salvage therapy for refractory high-risk langerhans cell histiocytosis.
Abraham A; Alsultan A; Jeng M; Rodriguez-Galindo C; Campbell PK
Pediatr Blood Cancer; 2013 Jun; 60(6):E19-22. PubMed ID: 23255383
[TBL] [Abstract][Full Text] [Related]
31. Longitudinal assessment of peripheral blood BRAFV600E levels in patients with Langerhans cell histiocytosis.
Schwentner R; Kolenová A; Jug G; Schnöller T; Ahlmann M; Meister B; Lehrnbecher T; Minkov M; Hutter C
Pediatr Res; 2019 May; 85(6):856-864. PubMed ID: 30474648
[TBL] [Abstract][Full Text] [Related]
32. [Status of Langerhans cell histiocytosis in children and adults].
Kudo K
Rinsho Ketsueki; 2019; 60(9):1308-1316. PubMed ID: 31597857
[TBL] [Abstract][Full Text] [Related]
33. Mutant PIK3CA is a targetable driver alteration in histiocytic neoplasms.
Durham BH; Hershkovitz-Rokah O; Abdel-Wahab O; Yabe M; Chung YR; Itchaki G; Ben-Sasson M; Asher-Guz VA; Groshar D; Doe-Tetteh SA; Alano T; Solit DB; Shpilberg O; Diamond EL; Mazor RD
Blood Adv; 2023 Dec; 7(23):7319-7328. PubMed ID: 37874915
[TBL] [Abstract][Full Text] [Related]
34. Langerhans cell histiocytosis of skull: a retrospective study of 18 cases.
Zhang XH; Zhang J; Chen ZH; Sai K; Chen YS; Wang J; Ke C; Guo CC; Chen ZP; Mou YG
Ann Palliat Med; 2017 Apr; 6(2):159-164. PubMed ID: 28061539
[TBL] [Abstract][Full Text] [Related]
35. Vinblastine chemotherapy in adult patients with langerhans cell histiocytosis: a multicenter retrospective study.
Tazi A; Lorillon G; Haroche J; Neel A; Dominique S; Aouba A; Bouaziz JD; de Margerie-Melon C; Bugnet E; Cottin V; Comont T; Lavigne C; Kahn JE; Donadieu J; Chevret S
Orphanet J Rare Dis; 2017 May; 12(1):95. PubMed ID: 28532436
[TBL] [Abstract][Full Text] [Related]
36. Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy.
Aricò M
Br J Haematol; 2016 Jun; 173(5):663-70. PubMed ID: 26913480
[TBL] [Abstract][Full Text] [Related]
37. Circulating cell-free BRAF
Héritier S; Hélias-Rodzewicz Z; Lapillonne H; Terrones N; Garrigou S; Normand C; Barkaoui MA; Miron J; Plat G; Aladjidi N; Pagnier A; Deville A; Gillibert-Yvert M; Moshous D; Lefèvre-Utile A; Lutun A; Paillard C; Thomas C; Jeziorski E; Nizard P; Taly V; Emile JF; Donadieu J
Br J Haematol; 2017 Aug; 178(3):457-467. PubMed ID: 28444728
[TBL] [Abstract][Full Text] [Related]
38. Clofarabine in refractory Langerhans cell histiocytosis.
Rodriguez-Galindo C; Jeng M; Khuu P; McCarville MB; Jeha S
Pediatr Blood Cancer; 2008 Nov; 51(5):703-6. PubMed ID: 18623218
[TBL] [Abstract][Full Text] [Related]
39. [Vemurafenib in refractory langerhans histiocytosis].
Raciborska A; Małas Z; Tysarowski A
Dev Period Med; 2018; 22(4):376-378. PubMed ID: 30636236
[TBL] [Abstract][Full Text] [Related]
40. [Treatment of children with multiple system Langerhans cell histiocytosis by Japan Langerhans Cell Histiocytosis Study Group Protocol].
Huang JB; Xue HM; Chen YY; Huang K
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):146-9. PubMed ID: 23484709
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
